JP5380553B2 - 放射性金属標識抗カドヘリン抗体 - Google Patents

放射性金属標識抗カドヘリン抗体 Download PDF

Info

Publication number
JP5380553B2
JP5380553B2 JP2011553868A JP2011553868A JP5380553B2 JP 5380553 B2 JP5380553 B2 JP 5380553B2 JP 2011553868 A JP2011553868 A JP 2011553868A JP 2011553868 A JP2011553868 A JP 2011553868A JP 5380553 B2 JP5380553 B2 JP 5380553B2
Authority
JP
Japan
Prior art keywords
antibody
nite
cadherin
metal
radioactive metal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011553868A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2011099524A1 (ja
Inventor
明弘 日野
朗夫 長埜
雅彦 渡邉
正 松浦
広一 佐藤
富美子 野村
克之 見供
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm RI Pharma Co Ltd
Perseus Proteomics Inc
Original Assignee
Fujifilm RI Pharma Co Ltd
Perseus Proteomics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm RI Pharma Co Ltd, Perseus Proteomics Inc filed Critical Fujifilm RI Pharma Co Ltd
Priority to JP2011553868A priority Critical patent/JP5380553B2/ja
Publication of JPWO2011099524A1 publication Critical patent/JPWO2011099524A1/ja
Application granted granted Critical
Publication of JP5380553B2 publication Critical patent/JP5380553B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/02—Preparation of hybrid cells by fusion of two or more cells, e.g. protoplast fusion
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Optics & Photonics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2011553868A 2010-02-10 2011-02-09 放射性金属標識抗カドヘリン抗体 Active JP5380553B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2011553868A JP5380553B2 (ja) 2010-02-10 2011-02-09 放射性金属標識抗カドヘリン抗体

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2010028028 2010-02-10
JP2010028028 2010-02-10
JP2011553868A JP5380553B2 (ja) 2010-02-10 2011-02-09 放射性金属標識抗カドヘリン抗体
PCT/JP2011/052759 WO2011099524A1 (ja) 2010-02-10 2011-02-09 放射性金属標識抗カドヘリン抗体

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2013200942A Division JP5848737B2 (ja) 2010-02-10 2013-09-27 放射性金属標識抗カドヘリン抗体

Publications (2)

Publication Number Publication Date
JPWO2011099524A1 JPWO2011099524A1 (ja) 2013-06-13
JP5380553B2 true JP5380553B2 (ja) 2014-01-08

Family

ID=44367795

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2011553868A Active JP5380553B2 (ja) 2010-02-10 2011-02-09 放射性金属標識抗カドヘリン抗体
JP2013200942A Active JP5848737B2 (ja) 2010-02-10 2013-09-27 放射性金属標識抗カドヘリン抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2013200942A Active JP5848737B2 (ja) 2010-02-10 2013-09-27 放射性金属標識抗カドヘリン抗体

Country Status (22)

Country Link
US (2) US8815211B2 (enExample)
EP (1) EP2535358B1 (enExample)
JP (2) JP5380553B2 (enExample)
KR (1) KR101900110B1 (enExample)
CN (1) CN102892787B (enExample)
AU (1) AU2011215267B2 (enExample)
BR (1) BR112012020116B8 (enExample)
CA (1) CA2789310C (enExample)
CY (1) CY1120012T1 (enExample)
DK (1) DK2535358T3 (enExample)
ES (1) ES2656168T3 (enExample)
HR (1) HRP20180293T1 (enExample)
HU (1) HUE037817T2 (enExample)
LT (1) LT2535358T (enExample)
NO (1) NO2535358T3 (enExample)
PL (1) PL2535358T3 (enExample)
PT (1) PT2535358T (enExample)
RS (1) RS57008B1 (enExample)
RU (1) RU2577125C2 (enExample)
SG (1) SG183272A1 (enExample)
SI (1) SI2535358T1 (enExample)
WO (1) WO2011099524A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025089383A1 (ja) 2023-10-26 2025-05-01 株式会社ペルセウスプロテオミクス ２２５Ａｃ標識抗ＣＤＨ３抗体

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO2535358T3 (enExample) * 2010-02-10 2018-05-19
JPWO2012176765A1 (ja) * 2011-06-24 2015-02-23 株式会社ペルセウスプロテオミクス 抗ヒトｐ−カドへリン（ｃｄｈ３）遺伝子組み換え抗体
US20150031988A1 (en) * 2011-09-16 2015-01-29 Eri Takeuchi Nano-particles for internal radiation therapy of involved area, and therapy system
AU2012376421A1 (en) 2012-04-04 2014-11-13 Perseus Proteomics Inc. Drug conjugate comprising anti-cdh3 (p-cadherin) antibody
ES2829597T3 (es) * 2013-02-15 2021-06-01 Perseus Proteomics Inc Anticuerpo humanizado anti-CDH3, conjugado de fármaco del mismo y utilización del mismo
WO2015181882A1 (ja) * 2014-05-27 2015-12-03 株式会社島津製作所 分岐型両親媒性ブロックポリマーを用いた分子集合体及び薬剤搬送システム
MX2016017393A (es) 2014-07-01 2017-09-05 Pfizer Diacuerpos heterodimericos biespecificos y sus usos.
UY36401A (es) 2014-11-14 2016-06-30 Novartis Ag Conjugados anticuerpos-fármacos
WO2017120557A1 (en) * 2016-01-09 2017-07-13 Arbele Limited Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment
CA3031198A1 (en) * 2016-08-19 2018-02-22 Fujifilm Toyama Chemical Co., Ltd. Composition containing buffer
EP3551745A4 (en) 2016-12-12 2020-07-15 Xcella Biosciences, Inc. SCREENING METHODS AND SYSTEMS USING MICROCAPILLARY NETWORKS
RU2657761C1 (ru) * 2017-05-29 2018-06-15 Федеральное государственное автономное образовательное учреждение высшего образования "Национальный исследовательский Томский политехнический университет" Способ диагностики опухоли
CA3156776A1 (en) 2019-11-08 2021-05-14 xCella Biosciences, Inc. Apparatus and methods for laser-based single cell recovery from microcapillary arrays
AU2024386376A1 (en) 2023-11-21 2026-05-28 3B Pharmaceuticals Gmbh P-cadherin ligands
CN121426958B (zh) * 2025-12-31 2026-03-24 北京大学人民医院 一种抗cdh3纳米抗体与应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522982A (ja) * 2001-05-31 2005-08-04 カイロン コーポレイション 癌治療のための標的としてのｐ−カドヘリン
JP2005532343A (ja) * 2002-05-29 2005-10-27 イミューノメディクス、インコーポレイテッド 脳およびｃｎｓ腫瘍の放射免疫治療のための方法および組成物
JP2006509744A (ja) * 2002-11-14 2006-03-23 ブラッコ　イメージング　エッセ　ピ　ア 変化したタンパク質を細胞表面に呈示する腫瘍の診断および処置のための薬剤
JP2008538909A (ja) * 2005-04-26 2008-11-13 ファイザー・インク Ｐ−カドヘリン抗体
JP2009528257A (ja) * 2006-02-28 2009-08-06 オンコセラピー・サイエンス株式会社 抗ｃｄｈ３抗体のエフェクター機能を用いて細胞を障害する方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58201994A (ja) 1982-05-21 1983-11-25 Hideaki Hagiwara 抗原特異的ヒト免疫グロブリンの生産方法
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4917878A (en) * 1988-05-02 1990-04-17 Thomas Jefferson University Novel use of a radiolabelled antibody against stage specific embryonic antigen for the detection of occult abscesses in mammals
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
EP0656941B1 (en) 1992-03-24 2005-06-01 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
CA2177367A1 (en) 1993-12-03 1995-06-08 Andrew David Griffiths Recombinant binding proteins and peptides
ATE340590T1 (de) 1994-07-13 2006-10-15 Chugai Pharmaceutical Co Ltd Gegen menschliches interleukin-8 gerichteter, rekonstituierter menschlicher antikörper
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO2000026672A1 (en) * 1998-10-30 2000-05-11 Georgetown University Diagnosis of breast cancer using antibody against cadherin-11
EP2275540B1 (en) 1999-04-09 2016-03-23 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CN103333860B (zh) 2000-10-06 2015-07-08 协和发酵麒麟株式会社 产生抗体组合物的细胞
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP2005514409A (ja) * 2001-12-28 2005-05-19 アブジェニックス・インコーポレーテッド Ｍｕｃ１８抗原に対する抗体の使用
EP1560597A4 (en) 2002-10-29 2007-06-27 Pharmacia Corp DIFFERENTIALLY EXPRESSED CANCER GENES, POLYPEPTIDES CODED THEREIN, AND METHOD OF USE THEREOF
JP4912153B2 (ja) * 2003-12-01 2012-04-11 イミューノメディクス、インコーポレイテッド タンパク質とキレート剤とのコンジュゲートを調製するための改良された方法
CN1977044A (zh) 2004-03-24 2007-06-06 肿瘤疗法科学股份有限公司 治疗胰腺癌的组合物和方法
KR20080083068A (ko) * 2004-05-24 2008-09-12 더 프록터 앤드 갬블 캄파니 킬레이팅제를 함유하는 비스포스포네이트의 고형의 장용 경구 투여 형태
CA2729403A1 (en) * 2008-06-30 2010-01-07 Oncotherapy Science, Inc. Anti-cdh3 antibodies labeled with radioisotope label and uses thereof
AU2010242338B2 (en) 2009-05-01 2013-12-19 Perseus Proteomics Inc. Anti-cadherin antibody
CN102781964B (zh) * 2009-12-28 2015-11-25 肿瘤疗法科学股份有限公司 抗cdh3抗体及其用途
NO2535358T3 (enExample) * 2010-02-10 2018-05-19

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005522982A (ja) * 2001-05-31 2005-08-04 カイロン コーポレイション 癌治療のための標的としてのｐ−カドヘリン
JP2005532343A (ja) * 2002-05-29 2005-10-27 イミューノメディクス、インコーポレイテッド 脳およびｃｎｓ腫瘍の放射免疫治療のための方法および組成物
JP2006509744A (ja) * 2002-11-14 2006-03-23 ブラッコ　イメージング　エッセ　ピ　ア 変化したタンパク質を細胞表面に呈示する腫瘍の診断および処置のための薬剤
JP2008538909A (ja) * 2005-04-26 2008-11-13 ファイザー・インク Ｐ−カドヘリン抗体
JP2009528257A (ja) * 2006-02-28 2009-08-06 オンコセラピー・サイエンス株式会社 抗ｃｄｈ３抗体のエフェクター機能を用いて細胞を障害する方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6013015389; Ｃｌｉｎ．　Ｃａｎｃｅｒ　Ｒｅｓ．，　（２００５），　Ｖｏｌ．　１１，　Ｎｏ．　９，　ｐ．　７０７０ｓ-７０７４ｓ *
JPN6013015393; Ｐｌｏｓ　ＯＮＥ，　（２００７），　Ｎｏ．　３，　ｅ　２６７ *
JPN6013015397; Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ，　（２００１），　Ｖｏｌ．　６１，　ｐ．　２８０４-２８０８ *
JPN6013015407; Ｃａｎｃｅｒ　Ｓｃｉｅｎｃｅ，　（２００５），　Ｖｏｌ．　９６，　Ｎｏ．　１２，　ｐ．　９０３-９１０ *
JPN7013001179; Ａｐｐｌｉｅｄ　Ｒａｄｉａｔｉｏｎ　ａｎｄ　Ｉｓｏｔｏｐｅｓ，　（２００２），　Ｖｏｌ．　５７，　ｐ．　８４１-８４７ *
JPN7013001180; Ｙａｋｕｇａｋｕｚａｓｓｈｉ，　（２００８），　Ｖｏｌ．　３，　ｐ．　３２３-３３２ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025089383A1 (ja) 2023-10-26 2025-05-01 株式会社ペルセウスプロテオミクス ２２５Ａｃ標識抗ＣＤＨ３抗体

Also Published As

Publication number Publication date
JP5848737B2 (ja) 2016-01-27
EP2535358B1 (en) 2017-12-20
CA2789310A1 (en) 2011-08-18
CN102892787B (zh) 2015-04-29
BR112012020116B1 (pt) 2021-12-14
ES2656168T3 (es) 2018-02-23
LT2535358T (lt) 2018-03-26
NO2535358T3 (enExample) 2018-05-19
HUE037817T2 (hu) 2018-09-28
CA2789310C (en) 2018-01-09
US20140328754A1 (en) 2014-11-06
EP2535358A1 (en) 2012-12-19
PL2535358T3 (pl) 2018-05-30
US8815211B2 (en) 2014-08-26
KR20120115995A (ko) 2012-10-19
US20130071324A1 (en) 2013-03-21
RS57008B1 (sr) 2018-05-31
EP2535358A4 (en) 2013-07-10
CY1120012T1 (el) 2018-12-12
RU2012138459A (ru) 2014-03-20
CN102892787A (zh) 2013-01-23
JPWO2011099524A1 (ja) 2013-06-13
EP2535358A9 (en) 2014-03-26
AU2011215267B2 (en) 2016-07-07
PT2535358T (pt) 2018-02-23
WO2011099524A1 (ja) 2011-08-18
BR112012020116A2 (pt) 2020-08-18
KR101900110B1 (ko) 2018-09-18
RU2577125C2 (ru) 2016-03-10
DK2535358T3 (en) 2018-02-05
AU2011215267A1 (en) 2012-09-06
JP2014012731A (ja) 2014-01-23
HRP20180293T1 (hr) 2018-03-23
SI2535358T1 (en) 2018-03-30
SG183272A1 (en) 2012-09-27
BR112012020116B8 (pt) 2023-01-10

Similar Documents

Publication Publication Date Title
JP5848737B2 (ja) 放射性金属標識抗カドヘリン抗体
JP6006640B2 (ja) 高い内在化能力を有する抗ｃｄｈ３抗体
EP2573120B1 (en) Anti-human trop-2 antibody having anti-tumor activity in vivo
US9127061B2 (en) Anti-human P-cadherin (CDH3) recombinant antibody
EP4458859A2 (en) Conjugate of anti-cdh3 (p-cadherin) antibody and drug
EP2426149A1 (en) Anti-cadherin antibody
WO2012057315A1 (ja) 高い親和性を有する抗cdh3抗体
WO2014126198A1 (ja) 抗ｃｄｈ３ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用
HK1175477A (en) Radioactive metal-labeled anti-cadherin antibody
HK1175477B (en) Radioactive metal-labeled anti-cadherin antibody
HK40034094A (en) Anti-cdh3 antibody having high internalization capacity
HK1261879B (en) Anti-cdh3 antibody having high internalization capacity
HK1261879A1 (en) Anti-cdh3 antibody having high internalization capacity
HK1188222A (en) Anti-cdh3 antibody having high internalization capacity
HK1166508A (en) Anti-cadherin antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130524

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130702

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130903

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130930

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

Ref document number: 5380553

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313115

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250